Trial reportClinical cardiology2001
Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia.
Trial report in Clinical cardiology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 102 citations in OpenAlex.
- Hydroxypropylmethylcellulose lowers cholesterol in statin-treated men and women with primary hypercholesterolemia.European journal of clinical nutrition · 2009Trial
- Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia.Digestive diseases and sciences · 2005Trial
- Importance and Management of Non-High-Density Lipoprotein Cholesterol in Dyslipidemia Treatment.JACC. Asia · 2026Review
- Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles.Journal of clinical medicine · 2021Review
- Role of colesevelam in combination lipid-lowering therapy.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2013Review
- Dyslipidemia in patients with chronic and end-stage kidney disease.Cardiorenal medicine · 2013Review
- Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl.Drugs & aging · 2012Review
- Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action.Core evidence · 2012Article
- Overcoming obstacles in risk factor management in type 2 diabetes mellitus.Journal of clinical hypertension (Greenwich, Conn.) · 2011Review
- Safety of simvastatin and goal attainment for low-density lipoprotein cholesterol in sultan qaboos university hospital.Oman medical journal · 2010Article
- Review
- Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children.Adolescent health, medicine and therapeutics · 2010Review
- Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam - a clinical perspective.Diabetes, metabolic syndrome and obesity : targets and therapy · 2009Article
- Statins and C-reactive protein levels.Journal of clinical hypertension (Greenwich, Conn.) · 2007Review
- Effective use of combination lipid therapy.Current atherosclerosis reports · 2006Article
- Effective use of combination lipid therapy.Current cardiology reports · 2005Review
- Successful Treatment with Colesevelam HCl and Pravastatin in a Patient Previously Hospitalised with Severe Normal CPK Myopathy on Introduction of Simvastatin.Clinical drug investigation · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColesevelam hydrochloride is a novel, lipid-lowering agent that binds bile acids with high affinity. A multicenter, randomized, double-blind, placebo-controlled, parallel-design study was conducted to assess the efficacy and tolerability of combination low-dose colesevelam and lovastatin treatment in patients with primary hypercholesterolemia. HYPOTHESIS: Combination therapy with low doses of colesevelam and lovastatin decreases low density (LDL) cholesterol with minimal adverse events.
methodsFollowing a 4- to 6-week dietary lead in, 135 patients were randomized into five groups for a 4-week treatment period: placebo, colesevelam 2.3 g at dinner, lovastatin 10 mg at dinner, the combination of colesevelam and lovastatin given at dinner (dosed together), and combination treatment with colesevelam given at dinner and lovastatin administered at bedtime (dosed apart).
resultsCombination colesevelam and lovastatin treatment decreased LDL cholesterol by 34% (60 mg/dl, p < 0.0001) and 32% (53 mg/dl, p < 0.0001) when colesevelam and lovastatin were dosed together or dosed apart, respectively. Both combination therapies were superior to either agent alone (p < 0.05). Decreases in LDL cholesterol exceeded the combined decreases observed for colesevelam alone (13 mg/dl, 7%) and lovastatin alone (39 mg/dl, 22%). Both combination treatments reduced total cholesterol by 21% (p < 0.0001) and apolipoprotein B by 24% (p < 0.0001). Neither combination treatment significantly altered high-density lipoprotein cholesterol or triglycerides. Adverse side effects were not significantly different among randomized groups.
conclusionsCombination colesevelam and lovastatin was efficacious and well tolerated, resulting in additive decreases in LDL cholesterol levels whether or not both agents were administered simultaneously.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.